https://www.live-feeds.com/feed/a-480-000-a-year-pill-reflects-a-new-normal-for-cancer-drugsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/a-480-000-a-year-pill-reflects-a-new-normal-for-cancer-drugshttps://www.live-feeds.com/feed/a-480-000-a-year-pill-reflects-a-new-normal-for-cancer-drugs#u54347Wed, 02 Sep 2026 04:03:05 +0000The FDA has approved a new pancreatic cancer drug priced at $480,000 per year. The drug is expected to transform care for pancreatic cancer patients and has been hailed as a breakthrough. It has shown to improve survival rates and is considered a significant advancement in the treatment of this intractable disease.Why it mattersPancreatic cancer is a highly aggressive and often fatal disease. The approved drug offers new hope for patients and marks a significant shift in treatment options. The high price of the drug has raised concerns about accessibility and affordability.What is confirmedThe